Literature DB >> 3763911

Diagnostic imaging of human neuroblastoma with radiolabeled antibody.

F D Miraldi, A D Nelson, C Kraly, S Ellery, B Landmeier, P F Coccia, S E Strandjord, N K Cheung.   

Abstract

In a previous study, the authors showed that iodine-131 labeled monoclonal antibody (Mab 3F8) could be used to image human neuroblastoma xenografts in mice with excellent tumor-to-tissue ratios. In this study they report their experience with six patients scanned with radiolabeled 3F8. There was strong accumulation of the labeled antibody in viable tumor, but no significant uptake was noted in normal brain, liver, spleen, or adrenal glands. Tumor-to-nontumor activity ratios varied but were approximately 10:1-20:1. This ratio yields good contrast for visualization. Time-activity curves show that radioactivity levels in normal tissue have a half-time of about 40 hours, whereas tumor tissues show a half-time of about 60 hours. Significant gastric secretion of free iodine demonstrated that the Mab was being deiodinated. Calculated radiation doses indicate that tumors receive at least ten times the dose to other tissues. The results indicate that Mab 3F8 has clinical potential for both imaging and therapy of human neuroblastomas.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3763911     DOI: 10.1148/radiology.161.2.3763911

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  11 in total

1.  Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study.

Authors:  Brian H Kushner; Kim Kramer; Shakeel Modak; Nai-Kong V Cheung
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

2.  Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.

Authors:  Maxim Yankelevich; Sri Vidya Kondadasula; Archana Thakur; Steven Buck; Nai-Kong V Cheung; Lawrence G Lum
Journal:  Pediatr Blood Cancer       Date:  2012-06-15       Impact factor: 3.167

Review 3.  Monoclonal antibody-based therapy for neuroblastoma.

Authors:  N K Cheung
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

4.  Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes.

Authors:  Kayleen Bailey; Neeta Pandit-Taskar; John L Humm; Pat Zanzonico; Stephen Gilheeney; Nai-Kong V Cheung; Kim Kramer
Journal:  J Neurooncol       Date:  2019-03-16       Impact factor: 4.130

5.  Positron Emission Tomography Detects In Vivo Expression of Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma.

Authors:  Elizabeth R Butch; Paul E Mead; Victor Amador Diaz; Heather Tillman; Elizabeth Stewart; Jitendra K Mishra; Jieun Kim; Armita Bahrami; Jason L J Dearling; Alan B Packard; Shana V Stoddard; Amy L Vāvere; Yuanyuan Han; Barry L Shulkin; Scott E Snyder
Journal:  Cancer Res       Date:  2019-04-23       Impact factor: 12.701

6.  Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates.

Authors:  K Kramer; N K Cheung; J Humm; G DiResta; E Arbit; S Larson; R Finn; M Rosenblum; H Nguyen; G Gonzalez; C Liu; Y F Yang; M E Mendelsohn; A P Gillio
Journal:  J Neurooncol       Date:  1997-11       Impact factor: 4.130

7.  Comparison of radiolabeled monoclonal antibody and magnetic resonance imaging in the detection of metastatic neuroblastoma in bone marrow: preliminary results.

Authors:  B D Fletcher; F D Miraldi; N K Cheung
Journal:  Pediatr Radiol       Date:  1989

8.  Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors.

Authors:  E Arbit; N K Cheung; S D Yeh; F Daghighian; J J Zhang; C Cordon-Cardo; K Pentlow; A Canete; R Finn; S M Larson
Journal:  Eur J Nucl Med       Date:  1995-05

9.  Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8.

Authors:  I Bergman; E Arbit; M Rosenblum; S M Larson; G Heller; N K Cheung
Journal:  J Neurooncol       Date:  1993-03       Impact factor: 4.130

10.  Potentiation of a weakly active ricin A chain immunotoxin recognizing the neural cell adhesion molecule.

Authors:  E J Derbyshire; R A Stahel; E J Wawrzynczak
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.